Peter S Hall

Summary

Affiliation: University of Leeds
Country: UK

Publications

  1. ncbi Expected net present value of sample information: from burden to investment
    Peter S Hall
    Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
    Med Decis Making 32:E11-21. 2012
  2. ncbi Current perspective - trastuzumab
    Peter S Hall
    University of Leeds, UK
    Eur J Cancer 45:12-8. 2009
  3. ncbi Health economics in drug development: efficient research to inform healthcare funding decisions
    Peter S Hall
    University of Leeds, Charles Thackrah Building, 101 Clarendon Road, Leeds LS2 9LJ, UK
    Eur J Cancer 46:2674-80. 2010
  4. ncbi Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence
    Peter S Hall
    Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
    Pharmacoeconomics 29:415-32. 2011
  5. ncbi Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer
    Peter S Hall
    Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, UK
    J Natl Cancer Inst 104:56-66. 2012

Detail Information

Publications5

  1. ncbi Expected net present value of sample information: from burden to investment
    Peter S Hall
    Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
    Med Decis Making 32:E11-21. 2012
    ..The investigators describe a development of the calculation of the expected value of sample information that assesses the value of investing in further research, including an only-in-research strategy and an only-with-research strategy...
  2. ncbi Current perspective - trastuzumab
    Peter S Hall
    University of Leeds, UK
    Eur J Cancer 45:12-8. 2009
    ..This article will review the available clinical data on the efficacy of trastuzumab in the treatment of both early advanced breast cancer...
  3. ncbi Health economics in drug development: efficient research to inform healthcare funding decisions
    Peter S Hall
    University of Leeds, Charles Thackrah Building, 101 Clarendon Road, Leeds LS2 9LJ, UK
    Eur J Cancer 46:2674-80. 2010
    ..The potential for decision theoretic methods to help overcome these problems is introduced and potential obstacles in implementation are highlighted...
  4. ncbi Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence
    Peter S Hall
    Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
    Pharmacoeconomics 29:415-32. 2011
    ..We present an updated cost-effectiveness analysis from the UK perspective, which explores assumptions about the duration of benefit from treatment, pattern of metastatic recurrence and long-term cardiac toxicity...
  5. ncbi Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer
    Peter S Hall
    Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, UK
    J Natl Cancer Inst 104:56-66. 2012
    ..This economic evaluation compared genomic test-directed chemotherapy using the Oncotype DX 21-gene assay with chemotherapy for all eligible patients with lymph node-positive, estrogen receptor-positive early-stage breast cancer...